Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10970224 | Vaccine | 2010 | 4 Pages |
Abstract
We evaluated a modified HBV regimen in a cohort of HIV-infected subjects in Rio de Janeiro, Brazil. HIV-infected subjects with no serologic evidences of previous hepatitis B infection were immunized with 4 doses (40 μg each) of recombinant hepatitis B vaccine given at 0, 1, 2 and 6 months. Blood samples were collected 1 month after the last dose and anti-HBs titers were measured. A protective antibody response was defined as an anti-HBs titer â¥10 mIU/mL. Forty-seven subjects (30 women, 17 men; mean age was 36 years, ranging from 21 to 58 years) were included in the final analysis. Median baseline CD4+ lymphocyte count was 402 cells/mm3 and 33 subjects (70%) had an HIV viral load below 80 copies/mL. A protective antibody response was observed in 42 (89%) subjects. Thirty-seven (78%) and 28 (60%) patients developed anti-HBs titers higher than 100 mIU/mL and 1000 mIU/mL, respectively. 1 out of 5 non-responders (20%) had an HIV viral load below the detection limit, in contrast with 32 (76%) of those with an adequate serologic response (p = 0.02). These findings suggest that 4-double dose alternative schedule may be considered to overcome the lower seroconversion rates observed with the standard regimens in HIV-infected subjects.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
D.V. Potsch, M.L.A. Oliveira, C. GinuÃno, J.C. Miguel, S.A.N. Oliveira, E.F. Silva, R.B. Moreira, G.V.M. Cruz, A.L.V.S.M. Oliveira, L.A.B. Camacho, P.F. Barroso,